Saturday 17 October 2026
Export REVB’s income statement to Excel — free account
Revelation Biosciences, Inc.
REVB Healthcare Biotechnology
In the quarter to June 2026, EPS grew 96.9% and free cash flow fell 35.3%, each against the same quarter a year earlier.
0.49
0.27
−35.53%
Follow REVB
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 1,965,600.00 | 1,971,648.00 | 34,070.40 | 2,712.96 | 53.95 | 3.04 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | 2,177,280.00 | 2,163,571.25 | 2,276,064.00 | 65,721.60 | 4,849.92 | 241.92 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 14 | 6 | 10 | 9 | 9 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | — | 0 | (2) | (12) | (11) | 0 | (15) | (9) | |||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | 0 | (2) | (12) | (11) | 0 | (15) | (9) | |||||
| Depreciation | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | 0.00 | (0.68) | (235,895.80) | (28,642.99) | (101.77) | (1,052.26) | (23.95) | |||||
| Cash flow | — | — | — | 0.00 | (0.09) | 0.00 | (28,048.50) | (6,071.92) | (1,308.66) | (13.32) | |||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (1.37) | 0.00 | |||||
| Free cash flow | — | — | — | 0.00 | (0.09) | 0.00 | (28,048.50) | (6,071.92) | (1,310.04) | (13.32) | |||||
| Book value | — | — | — | (0.01) | (2.36) | 0.00 | 2,631.25 | 5,539.75 | 336.31 | 14.27 | |||||
| Shares, m | — | — | — | 0 | 2 | 0 | 0 | 0 | 0 | 1 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | (11) | (11) | (7) | (18) | (8) | ||||
| Capex | — | — | — | — | — | 0 | — | — | 0 | — | |||||
| Free cash flow | — | — | — | — | 0 | (11) | (11) | (7) | (18) | (8) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 0 | (3) | 0 | 1 | 7 | 5 | 9 | ||||
| Total debt | — | — | — | — | — | 0 | — | — | — | — | |||||
| Net debt | — | — | — | — | (1) | (1) | (5) | (12) | (6) | (11) | |||||
| Shareholders’ equity | — | — | — | 0 | (6) | 0 | 1 | 7 | 5 | 9 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (31.72) | (4.40) | (31.46) | (287.04) | (1.36) | (159.69) | (163.31) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | (0.01) | 57.25 | 413.94 | (2,272.74) | (3.12) | (264.85) | (219.10) | |||||
Negative figures in brackets.
Charts ten years each
Revelation Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| EOCN Eocene Ltd. | $3.2M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −67.74% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| SXTP 60 Degrees Pharmaceuticals Inc. | $3.2M | — (loss-making) | — (loss-making) | −32.48% (below 0%: shrinking) | n/m | −54.33% (below 0%: shrinking) | 27.32% | (1,092.40%) | Compare |
| APVO Aptevo Therapeutics Inc. | $3.1M | 0.0× | — (loss-making) | +28.62% (above 0%: growing) | n/m | +23.11% (above 0%: growing) | 0.00% | 0.00% | Compare |
| GRI GRI Bio, Inc. | $3.1M | 0.0× | — (loss-making) | — | n/m | +54.33% (above 0%: growing) | 0.00% | 0.00% | Compare |
| REVB Revelation Biosciences, Inc. | $3.0M | — (loss-making) | — | — | n/m | −35.29% (below 0%: shrinking) | 0.00% | 0.00% | |
| ARAV ARAVIVE, INC | $3.0M | — (loss-making) | — (loss-making) | −44.39% (below 0%: shrinking) | n/m | +48.19% (above 0%: growing) | 100.00% | (323.44%) | Compare |
| DCOY Decoy Therapeutics Inc | $2.9M | 0.0× | — (loss-making) | −84.61% (below 0%: shrinking) | n/m | −212.47% (below 0%: shrinking) | 100.00% | (1,055.98%) | Compare |
| MBIO Mustang Bio, Inc. | $2.9M | — (loss-making) | — | — | n/m | +27.78% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BCAB BioAtla, Inc. | $2.9M | — (loss-making) | — (loss-making) | +4,233.33% (above 0%: growing) | n/m | +97.03% (above 0%: growing) | 100.00% | 3.49% | Compare |
| Median of peers | $3.0M | 0.0× | — | −38.43% | — | +25.45% | 13.66% | 0.00% |
Revelation Biosciences, Inc. (REVB) key facts
- Revelation Biosciences, Inc. (REVB) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, REVB traded at $0.49, a market capitalization of $3.0 million.
- Return on equity was −219.1% and debt-to-equity 0.00.
Revelation Biosciences, Inc. (REVB) Latest News
No news at this impact. Lower the threshold for more.